Related Experiment Video
Updated: Jun 21, 2025
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
CD73 Is an Immunometabolic Biomarker of Poor Prognosis in Patients With Primary Cutaneous Squamous Cell Carcinoma and
Vahide Saeidi1, Stephanie R Jackson Cullison, Nicole A Doudican
1All authors are affiliated with the Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York.
Background:
Impaired immunity may drive the increased incidence and aggression of cutaneous squamous cell carcinoma (cSCC) in patients with hematologic malignancy; however, precise mechanisms and prognostic biomarkers remain undefined. CD73 maintains elevated immunosuppressive adenosine levels and is associated with poor prognosis in several tumor microenvironments.
Objective:
Identify poor outcome biomarkers in patients with cSCC and hematologic malignancy.
Materials And Methods:
Differentially expressed genes in tumors from patients with hematologic malignancy experiencing good ( n = 8) versus poor ( n = 7) outcomes were identified by NanoString analysis. Results were validated at the protein level using CD73 immunohistochemistry in cSCC patients with ( n = 38) and without ( n = 29) hematologic malignancy.
Results:
Forty-eight genes were differentially expressed in tumors from patients with hematologic malignancy experiencing good versus poor outcomes. CD73 gene expression was >2-fold higher in patients with poor versus good outcomes or normal skin. Significantly increased CD73 protein levels were observed in cSCC tumors with poor versus good outcomes from patients with hematologic malignancies ( p < .01), whereas no differences were noted in tumors with poor versus good outcomes from patients without hematologic malignancies ( p = .49).
Conclusion:
CD73 is highly expressed in poor prognosis cSCC from patients with hematologic malignancy and may represent a useful biomarker and potential therapeutic target.
More Related Videos
09:08Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018